

Year_ Month	Session Topic	Session Purpose	Content	Topic Category	Consequences
2010_04	<b>Impact of New Vaccine Introduction on Immunization and Health Systems</b>	For Decision	Guidance is sought from SAGE on the direction of further research efforts. The discussion will focus on reviewing the available evidence/lack of evidence and on the scope of future work- the impact of new vaccine introduction on the immunization system and/or on the broader health system- as well as on the main use of the results of this research. The WHO Health System Building Blocks are proposed as framework for this work.	Programmatic challenge	A peer-reviewed publication and the 2014 WHO document, Principles and considerations for adding a vaccine to a national immunization programme <a href="http://www.who.int/immunization/programmes_systems/policies_strategies/vaccine_intro_resources/nvi_guidelines/en/">http://www.who.int/immunization/programmes_systems/policies_strategies/vaccine_intro_resources/nvi_guidelines/en/</a>
2010_04	<b>Pertussis vaccines</b>	For Decision	Provide updated recommendations on vaccine use (with a view to update the 2005 position paper). At its October 2009 meeting, SAGE concluded on the issue of pertussis control goals and surveillance and discussed the primary immunization schedule. SAGE will now be asked to review recommendations from the Working Group with respect to vaccine issues (such as comparative evaluation of aP and wP and supplementary immunization activities). It is hoped that the session will result in a complete set of recommendations and instructions for the Secretariat to update the pertussis vaccine position paper. Scheduled publication date for the position paper is 1 October 2010.	Vaccine specific	SAGE endorsed the establishment of a pertussis-vaccine strain repository and a database on the genealogy and characteristics of different vaccine strains. A proposal will be presented to the Expert Committee on Biological Standardization.  SAGE Meeting Report: <a href="http://www.who.int/wer/2010/wer8522.pdf?ua=1">http://www.who.int/wer/2010/wer8522.pdf?ua=1</a>
2010_04	<b>Influenza vaccines (H1N1 and H5N1 related issues)</b>	For Decision	Update on current SAGE recommendations on H1N1 pandemic vaccination: – What is the experience to date on safety, immunogenicity and effectiveness of pandemic vaccines? – Where are the priority areas for A(H1N1) vaccination? – Are the priority groups identified in July 2009 still to be targeted by vaccination? – How many doses are needed for various populations to maximize public health benefit?	Vaccine specific	In light of new data from ongoing pandemic, SAGE concluded that no changes were necessary to previous recommendations made by SAGE on priority target groups for vaccination or the number of doses needed;

			<p>Agreement on plan to be proposed by SAGE Working Group to review 2009 H5N1 vaccine recommendations.</p> <p>Questions proposed for review:</p> <ul style="list-style-type: none"> <li>– Is the establishment of a WHO stockpile of H5N1 vaccine still warranted?</li> <li>– What are the proposed uses for the WHO stockpile, and what size should the stockpile have?</li> <li>– Which populations, if any, should be vaccinated with H5N1 vaccine in the interpandemic period?</li> </ul> <p>Discuss the need to update the position paper on seasonal influenza vaccines and possible timelines.</p>		Decision to update WHO's position paper on seasonal influenza vaccination
2010_04	<b>Polio Eradication</b>	For Decision	<p>Update SAGE on the current epidemiological situation of polio and risks.</p> <p>Seek SAGE comments on the new GPEI Strategic Plan 2010-12.</p> <p>Request SAGE concurrence with the proposed monitoring plan for the Strategic Plan milestones. Review the proposed recommendations from the draft polio vaccine position paper. Scheduled publication date for the position paper is 4 June 2010.</p>	Vaccine specific	<p>Polio Position Paper June 2010  <a href="http://www.who.int/wer/2010/wer8523.pdf?ua=1">http://www.who.int/wer/2010/wer8523.pdf?ua=1</a></p>
2010_11	<b>Seasonal Influenza and H5N1 pandemic influenza vaccine</b>	For Decision	<p>Provide revised recommendations on the use of H5N1 vaccines and on the WHO H5N1 stockpile</p> <p>Present SAGE with an update of the work of SAGE working group on influenza vaccines and immunization</p>	Vaccine specific	<p>SAGE provided recommendations for the 2009 pandemic lessons learned report</p> <p>Insufficient evidence to warrant change in recommendations regarding H5N1 vaccination</p> <p>SAGE endorsed the scope of work for the review of the seasonal influenza position</p>
2010_11	<b>Polio eradication</b>	For Decision	<p>Report on SAGE recommendation to establish an independent monitoring and 'corrective action' process for the new Strategic Plan.</p>	Vaccine specific	<p>SAGE Meeting Report:  <a href="http://www.who.int/wer/2011/wer8601_02.pdf?ua=1">http://www.who.int/wer/2011/wer8601_02.pdf?ua=1</a></p>

			<p>Obtain SAGE perspectives on the impact to date of the Strategic Plan 2010-12 and the risks to completing polio eradication.</p> <p>For SAGE decision on (a) whether to extend the WG's timeline for its 2nd deliverable (post eradication polio immunization recommendations for low-income settings) to April 2012, and (b) expanding the mandate of the WG to include whether to continue immunizing against type 2 poliovirus in advance of type 1 &amp; 3 eradication.</p>		
2010_11	<b>Feasibility of measles eradication</b>	For Decision	<p>For decision on the recommendation of the ad hoc advisory group for the global technical consultation meeting to assess the feasibility of measles eradication which include the following:</p> <ul style="list-style-type: none"> <li>• Can and should measles be eradicated?</li> <li>• Is 2020 a feasible target for achieving measles eradication?</li> <li>• Should WHA consider establishing a target date for measles eradication once the South-East Asian Region has established an elimination target?</li> </ul> <p>SAGE recommendations will then be presented to the WHA in May 2011</p>	Vaccine specific	<p>SAGE concluded that measles can and should be eradicated. A goal for measles eradication should be established with a pro-proposed target date based on measurable progress made towards existing goals and targets. The eradication of measles represents unique disease control and developmental opportunities and should be carried out in the context of strengthening routine immunization programmes.</p> <p>SAGE Meeting Report:  <a href="http://www.who.int/wer/2011/wer8601_02.pdf?ua=1">http://www.who.int/wer/2011/wer8601_02.pdf?ua=1</a> </p>
2011_04	<b>Tick-borne encephalitis</b>	For Decision	<p>Review evidence on epidemiology and burden of tick-borne encephalitis, and on tick-borne encephalitis vaccines and their performance.</p> <p>-Recommendations on the use of tick-borne encephalitis vaccines leading to the publication of a vaccine position paper.</p>	Vaccine specific	<p>June 2011 Tick-borne encephalitis vaccine position paper  <a href="http://www.who.int/wer/2011/wer8624.pdf?ua=1">http://www.who.int/wer/2011/wer8624.pdf?ua=1</a> </p>

2011_04	<b>Meningococcal meningitis vaccines</b>	For Decision	Recommendations on the use of meningococcal meningitis vaccines in different settings (endemic, non-endemic, and outbreak regions) with a view to update the WHO vaccine position paper.	Vaccine specific	updating of the 2002 WHO vaccine position paper November 2011 Position Paper: <a href="http://www.who.int/wer/2011/wer8647.pdf?ua=1">http://www.who.int/wer/2011/wer8647.pdf?ua=1</a>
2011_04	<b>Rubella vaccination</b>	For Decision	Propose necessary updating of WHO recommended vaccination strategies for use of rubella vaccines according to the disease control goal for rubella and congenital rubella syndrome (CRS). -The specific questions to be addressed are: What are the possible disease control goals for rubella and congenital rubella syndrome? For each goal, what are the most appropriate vaccination strategies? What is the minimum required immunization coverage that should be achieved and maintained to ensure that the introduction of rubella-containing vaccine does not increase the risk of CRS? -The recommendations from SAGE will be used to update the WHO Rubella Vaccines position paper.	Vaccine specific	July 2011 Rubella vaccine position paper <a href="http://www.who.int/wer/2011/wer8629.pdf?ua=1">http://www.who.int/wer/2011/wer8629.pdf?ua=1</a>
2011_11	<b>Optimizing immunization schedules for conjugate pneumococcal vaccines</b>	For Decision	SAGE will be presented with a critical review of the evidence for various PCV schedule(s) and to compare them to the 3-dose primary schedule currently recommended. SAGE will be asked to: • decide on optimal PCV childhood schedule(s). -Number of doses: 2 or 3 primary doses and interval between doses -Age at 1st dose -Need for a booster dose and if so recommended age -PCVs interchangeability Co-administration with other EPI vaccines.	Vaccine specific	April 2012 Pneumococcal vaccine position paper <a href="http://www.who.int/wer/2012/wer8714.pdf?ua=1">http://www.who.int/wer/2012/wer8714.pdf?ua=1</a>

			<ul style="list-style-type: none"> <li>• identify data gaps and limitations of existing evidence to inform PCV schedules selection at country and regional level.</li> <li>• identify priority research questions to inform future PCV schedules policy.</li> </ul>		
2011_11	<b>Polio eradication</b>	For Decision	<p>SAGE's comments on, and potential endorsement of the new strategic approach to the endgame that would combine the eradication of residual wild polio viruses (WPVs) and elimination of vaccine derived polio virus (VDPV) type 2.</p> <p>SAGE's comment on the operational priorities and any potential adjustments.</p> <p>SAGE's opinion as to what role IPV might play in the context of wild poliovirus eradication and which, if any, additional research studies or evaluation projects should be undertaken to guide strategy in this regard.</p>	Vaccine specific	<p>SAGE agreed in principle that WHO should pursue a pre-eradication switch from trivalent oral poliovirus vaccine (tOPV) to bivalent oral poliovirus vaccine (bOPV) for routine immunization, and reaffirmed the desirability of a phased rather than simultaneous removal of Sabin polioviruses.</p> <p>SAGE meeting Report  <a href="http://www.who.int/wer/2012/wer8701.pdf?ua=1">http://www.who.int/wer/2012/wer8701.pdf?ua=1</a></p>
2011_11	<b>Evidence and recommendations for use of hepatitis A vaccines</b>	For Decision	<p>For review of evidence and decision on recommendations for use of hepatitis A vaccines in global immunization programmes to prepare for the updating of the 2000 hepatitis A WHO position paper</p> <p>Specific expected output:</p> <ul style="list-style-type: none"> <li>• Request endorsement of proposed recommendations for updated vaccine policies and for the expanded use of hepatitis A vaccines in general populations as well as in specific risk populations.</li> <li>• Request endorsement of proposed recommendation to continue to monitor safety and long-term protection of hepatitis A vaccines.</li> </ul>	Vaccine specific	June 2012 Hepatitis A vaccine position paper

<b>2012_02</b>	<b>GVAP</b>	For Decision	Present SAGE with the Global Vaccine Action Plan (GVAP) revised as a result of the consultative process and ask for SAGE's endorsement of this action plan and/or necessary modification prior to the document being submitted to the WHA.	Decade of Vaccines	Detailed technical and strategic input into revised draft Global Vaccine Action Plan (GVAP)
<b>2012_04</b>	<b>Polio eradication</b>	For Decision	Does SAGE feel that the planned actions in Nigeria, Pakistan, and Afghanistan address the main gaps? Does SAGE concur with the suggested order of priorities for emergency activities in response to the financing gap? SAGE to consider specific recommendations for the synchronous replacement of tOPV with bOPV for routine immunization globally by April 2014, preceded 6 months beforehand by the introduction of a supplementary dose of IPV (given IM or as a fractional dose ID) at the DPT3 contact.	Vaccine specific	SAGE urged all governments and partners to act immediately to fill the funding gap in order to ensure the success of global polio eradication. SAGE urged that the Global Emergency Action Plan outline mechanisms to realize the synergies between polio eradication and strengthening of routine immunization. SAGE reaffirmed that a tOPV – bOPV switch should be conducted and provided recommendations on timelines and criteria
<b>2012_04</b>	<b>Seasonal influenza vaccine</b>	For Decision	SAGE recommendations on the use of seasonal influenza vaccines with particular focus on key target groups. SAGE recommendation on prioritization of immunization for risk groups. SAGE recommendations on the need to update the 2003 WHA coverage goals and to set specific coverage goals in various target groups.	Vaccine specific	Revision of the 2005 WHO position paper + recommendations on risk groups in SAGE Report: <a href="http://www.who.int/wer/2012/wer8721.pdf?ua=1">http://www.who.int/wer/2012/wer8721.pdf?ua=1</a>

<b>2012_04</b>	<b>Rotavirus vaccine schedules</b>	For Decision	<p>Present SAGE with available evidence on the benefits and risks of the current (and alternative) rotavirus immunization schedules for children living in different income strata/mortality settings?</p> <p>Secure SAGE recommendations on the optimal schedules for rotavirus vaccines for children living in different income strata/mortality settings?</p>	Vaccine specific	<p>January 2013 Rotavirus vaccine position paper</p> <p><a href="http://www.who.int/wer/2013/wer8805.pdf?ua=1">http://www.who.int/wer/2013/wer8805.pdf?ua=1</a></p>
<b>2012_04</b>	<b>Use of hepatitis A vaccines: Evidence and recommendations on the flexibility of a booster dose of inactivated hepatitis A vaccine with focus on long-term protection achieved by single dose administration</b>	For Decision	<p>In addition to previous recommendations on the use of hepatitis A vaccines, and which it will not be asked to revisit, SAGE will be asked to specifically answer the following question:</p> <p>Is a single dose vaccination with inactivated hepatitis A sufficient enough to provide long-term protection?</p>	Vaccine specific	<p>July 2012 Hepatitis A vaccine position paper</p> <p><a href="http://www.who.int/wer/2012/wer8728_29.pdf?ua=1">http://www.who.int/wer/2012/wer8728_29.pdf?ua=1</a></p>

---

<b>2012_11</b>	<b>Global polio eradication initiative</b>	For Decision	<p>Update SAGE on major developments since the April 2012 SAGE meeting</p> <p>Request SAGE's input on what additional issues should be addressed or considered in the polio endgame strategy, and to optimize the legacy of the Global Polio Eradication Initiative.</p> <p>Request a decision on the role of IPV in OPV cessation - should the current SAGE recommendation be revised in light of additional information on IPV options, prices, supply, delivery routes and impact on mucosal immunity. Request SAGE's view on the role for expanding the target age groups for bOPV campaigns and/or including IPV in campaigns.</p>	Vaccine specific	<p>SAGE recommended that all countries should introduce at least 1 dose of IPV in their routine immunization programme to mitigate the risks associated with the withdrawal of OPV2. For further recommendations please see SAGE Report</p> <p><a href="http://www.who.int/wer/2013/wer8801.pdf?ua=1">http://www.who.int/wer/2013/wer8801.pdf?ua=1</a></p>
<b>2012_11</b>	<b>GVAP</b>	For Decision	<p>Discuss DoV M&amp;E/Accountability Framework structure and provide feedback on the reporting process particularly where WHO leads and next steps. Request endorsement of the GVAP indicators to be presented to WHO EB. Provide feedback and endorse the DoV commitment guidelines for increased emphasis on immunization as part of the UN Secretary General's Global Strategy for Women's and Children's Health. Provide feedback on the process to undertake resource tracking process and update the GVAP cost, financing, and impact projections for 2015. Provide feedback on the proposed review process and reporting cycle.</p>	Decade of Vaccines	<p>SAGE made specific comments and recommendations on monitoring indicators see SAGE Report</p> <p><a href="http://www.who.int/wer/2013/wer8801.pdf?ua=1">http://www.who.int/wer/2013/wer8801.pdf?ua=1</a></p>
<b>2012_11</b>	<b>Hib immunization schedules</b>	For Decision	<p>What are the optimal schedules for Hib vaccines for children living in different epidemiological settings? What evidence is available on the current Hib vaccines schedules versus alternative schedules OR</p> <p>What schedules does the evidence favours (i.e. effectiveness, co-administration, operational issues, costs) for children living in different epidemiological settings?</p>	Vaccine specific	<p>September 2013 Hib vaccine position paper</p> <p><a href="http://www.who.int/wer/2013/wer8839.pdf?ua=1">http://www.who.int/wer/2013/wer8839.pdf?ua=1</a></p>

<b>2012_11</b>	<b>Vaccination in humanitarian emergencies</b>	For Decision	Request SAGE's review and endorsement of the decision-making framework on the use of vaccines in acute humanitarian emergencies.	Programmatic challenge	WHO strategy and various 2017 WHO documents on vaccination in humanitarian emergencies <a href="http://www.who.int/immunization/programmes_systems/policies_strategies/vaccination_humanitarian_emergencies/en/">http://www.who.int/immunization/programmes_systems/policies_strategies/vaccination_humanitarian_emergencies/en/</a>
<b>2013_04</b>	<b>Yellow fever</b>	For Decision	<p>Present SAGE with the report of the SAGE working group on yellow fever vaccines and request SAGE's endorsement of the proposed recommendations. Specifically, SAGE will be asked to:</p> <ul style="list-style-type: none"> <li>• Reconsider the need for booster doses every 10 years;</li> <li>• Review the safety profile of the vaccines and update the recommendations in the context of safety issues including in particular with respect to immunization of HIV infected populations and immunocompromised, in pregnant or lactating women, people over 60 years old and in context of viscerotropic and neurological diseases;</li> <li>• Review the role of routine vaccination versus outbreak control;</li> <li>• Review the impact of the combined vaccination strategy (routine immunization and preventive campaigns);</li> <li>• Review of interference between yellow fever and other vaccines and co-administered vaccination.</li> </ul> <p>SAGE will also be asked to identify critical research questions.</p> <p>SAGE recommendations on vaccine use will then be used to update the 2003 WHO position paper on the use of yellow fever vaccines.</p>	Vaccine specific	July 2013 Yellow fever vaccine position paper <a href="http://www.who.int/wer/2013/wer8827.pdf?ua=1">http://www.who.int/wer/2013/wer8827.pdf?ua=1</a>

2013_11	<b>Global polio eradication initiative</b>	For Decision	<p>For decision:</p> <ul style="list-style-type: none"> <li>• Optimal schedule for 1 IPV dose, • Strategic framework for responding to type 2 virus detection post-OPV2 cessation, • Recommendation for a WHA resolution in 2014 on accelerated IPV introduction, based on the progress toward a global supply and financing strategy</li> </ul> <p>For discussion:</p> <ul style="list-style-type: none"> <li>• Strategy to ensure bOPV access to all OPV-using countries, Criteria to assess global readiness for global OPV2 withdrawal</li> </ul>	Vaccine specific	SAGE endorsed the proposed strategy see SAGE Report <a href="http://www.who.int/wer/2014/wer8901.pdf?ua=1">http://www.who.int/wer/2014/wer8901.pdf?ua=1</a>
---------	--	--------------	---	------------------	---

2013_11	<b>GVAP progress report</b>	For Decision	<p>SAGE will be expected to produce an independent first report on progress with the Decade of Vaccines Global Vaccine Action Plan.</p> <p>Specially, SAGE will be asked to:</p> <ul style="list-style-type: none"> <li>- Review the DoV WG “Assessment report on DoV progress” based on: <ul style="list-style-type: none"> <li>• the review of the “annual report on the Decade of Vaccines progress” prepared by the DOV secretariat,</li> <li>• Information provided by other partners’ annual reports on Decade of Vaccines progress.</li> </ul> </li> <li>- Make recommendations on any necessary changes to the formulation of the indicators, operational definitions and/or the processes for data collection.</li> <li>- Identify successes, challenges and areas where additional efforts or corrective actions by countries, regions, partners, donor agencies or other parties, are needed.</li> <li>- Provide recommendations and corrective actions for Members States, regions, partners, donor agencies or other parties regarding DoV GVAP implementation in a “SAGE Assessment report on the Decade of Vaccines progress” which will be the basis of the “progress report” for the WHO Board and World Health Assembly.</li> </ul>	Decade of Vaccines	<p>See GVAP Assessment Report  <a href="http://www.who.int/immunization/global_vaccine_action_plan/OMS-IVB-AssessmentReport-20131212v5.pdf?ua=1">http://www.who.int/immunization/global_vaccine_action_plan/OMS-IVB-AssessmentReport-20131212v5.pdf?ua=1</a></p>
---------	-------------------------------------	-----------------	---	--------------------------	--

<b>2013_11</b>	<b>Pandemic and pre-pandemic influenza vaccine</b>	For Decision	<p>For information</p> <p>An update on the epidemiology of H7N9 and progress on vaccine development will also be provided. SAGE will be asked to discuss information to be collected on H7N9 cases of emerging virus in order to facilitate policy recommendations</p> <p>For decision</p> <p>In the context of the Pandemic Influenza Preparedness framework, review the previous recommendations on the establishment and use of an H5N1 vaccine stockpile</p> <p>Review the current recommendations on inter-pandemic use of H5N1 vaccines.</p>	Vaccine specific	<p>SAGE recommended policies for the establishment and use of influenza A(H5N1) vaccine stockpiles during a pandemic and in 2009, guidelines for the use of A(H5N1) vaccines during the inter-pandemic period. See SAGE Report <a href="http://www.who.int/wer/2014/wer8901.pdf?ua=1">http://www.who.int/wer/2014/wer8901.pdf?ua=1</a></p>
<b>2013_11</b>	<b>Measles and rubella elimination</b>	For Decision	<p>For discussion:</p> <ul style="list-style-type: none"> <li>• Global status report, • Report from each Region, • How to get back on track towards global and Regional targets, list of priority health workers</li> </ul> <p>For decision:</p> <ul style="list-style-type: none"> <li>• Use of combined measles-rubella vaccine for both routine doses, • Criteria to guide countries on expansion of the target age range measles and measles-rubella SIAs</li> </ul> <p>For decision:</p> <ul style="list-style-type: none"> <li>• Vaccination of health workers</li> </ul>	Vaccine specific	

2013_11	<b>Smallpox vaccines</b>	For Decision	<p>The last case of Smallpox occurred in 1977. In 1980 the World Health Assembly declared this disease eradicated. A global stockpile of vaccines, held in Switzerland, was created with donations from Member States. In 2004 Previous the Ad-Hoc Orthopoxvirus Committee, recommended that the stockpile should consist 200 million doses. The current physical WHO stockpile is ~ 2.4 million doses, and the virtual stockpile consists of 31 million doses. In order for WHO to make an informed decision (risk/benefit) on which vaccines to stock and to be able to give advice to countries on their stockpile, WHO would like SAGE to answer the following questions:</p> <p>Which vaccine should be recommended to be used during an outbreak of smallpox? (vaccine used during the eradication, vaccine produced in tissue cell, or further attenuated vaccines).</p> <p>–Composition of stockpile</p> <p>–Size of stockpile</p> <p>What groups should be prioritized to be vaccinated while faced with limited vaccine supply?</p> <p>–Age groups, risk factors/safety aspects, vulnerable populations, ethical considerations</p> <p>–Which vaccine should be given?</p> <p>Which vaccine should be recommended for preventive use?</p> <p>Who should be targeted and with which immunization schedule? (First aid responders, army, police, health workers)</p>	Vaccine specific	<p>See list of recommendations in SAGE report  <a href="http://www.who.int/wer/2014/wer8901.pdf?ua=1">http://www.who.int/wer/2014/wer8901.pdf?ua=1</a></p>
---------	--------------------------	--------------	--	------------------	--

<b>2014_04</b>	<b>Global polio eradication initiative</b>	For Decision	<p>For decision:</p> <ul style="list-style-type: none"> <li>· Vaccination requirements for the travelers from polio infected countries</li> <li>· Target date for global readiness for OPV2 withdrawal</li> </ul> <p>For discussion:</p> <ul style="list-style-type: none"> <li>· Progress in eliminating wild and vaccine derived poliovirus</li> <li>· Status of the preparation for global OPV2 withdrawal</li> </ul>	Vaccine specific	Recommendation for Travelers in context of ITH, SAGE endorsed the broad outlines of the proposed approach for mitigating the risk of cVDPV2 emergence at the time of OPV2 withdrawal See SAGE Report <a href="http://www.who.int/wer/2014/wer8921.pdf?ua=1">http://www.who.int/wer/2014/wer8921.pdf?ua=1</a>
<b>2014_04</b>	<b>Varicella and herpes zoster vaccines</b>	For Decision	Revision of data regarding the global prevalence and burden of disease caused by varicella and herpes zoster according to country development status, as well as revision of safety, effectiveness and duration of protection following varicella and herpes zoster vaccines. Proposed recommendations to SAGE on the use of varicella and herpes zoster vaccines.	Vaccine specific	June 2014 Varicella and herpes zoster vaccine position paper <a href="http://www.who.int/wer/2014/wer8925.pdf?ua=1">http://www.who.int/wer/2014/wer8925.pdf?ua=1</a>
<b>2014_04</b>	<b>Alternative vaccination schedules for HPV vaccines</b>	For Decision	To assess the effect on relevant immunological and clinical outcomes of 2 versus 3 doses of HPV vaccines in adolescent girls 9-13 years of age. To assess the effect immunological and clinical outcomes of various intervals between the first dose and the subsequent doses of HPV vaccines in girls 9-13 years of age (short versus delayed schedules). Expected output: Revised vaccination schedule for HPV vaccines in the above mentioned group.	Vaccine specific	<p>October 2014 HPV vaccine position paper</p> <p>Human papillomavirus vaccines: WHO position paper, October 2014</p> <p>Wkly Epidemiol Rec, 89 (43) (2014), pp. 465-492</p>

<b>2014_04</b>	<b>Pertussis vaccines</b>	For Decision	<p>Review epidemiological data on pertussis from selected countries using acellular pertussis (aP) and/or whole cell pertussis (wP) vaccines, to evaluate the evidence for resurgence of pertussis, with an emphasis on severe pertussis in very young infants. In countries where the evidence supports resurgence, evaluate the evidence for the hypothesis that this is due to shorter lived protection from aP than wP vaccines.</p> <p>Review the evidence on effectiveness of strategies aimed at reducing severe disease, and deaths in very young infants.</p> <p>Update recommendations on the use of pertussis vaccines.</p>	Vaccine specific	Specific recommendation of wP vs aP vaccine use in primary vaccination, Conditional recommendation on vaccination of pregnant women see SAGE Report <a href="http://www.who.int/wer/2014/wer8921.pdf?ua=1">http://www.who.int/wer/2014/wer8921.pdf?ua=1</a>
<b>2014_04</b>	<b>Non-specific effects of vaccines on mortality in children under 5 years of age</b>	For Decision	<p>Review of the available evidence that addresses the effect of BCG, DTP and measles-containing vaccines on survival/all-cause mortality in children less than five years of age and, the outcomes of the above-mentioned reviews and related GRADE tables.</p> <p>Expected output:</p> <p>SAGE recommendation on whether or not the current evidence is sufficient to lead to adjustments in policy recommendations or to warrant further scientific investigation.</p>	Vaccine safety	Assessment on NSE, request to develop study protocols< variouse publications from Working Group (see SAGE Report <a href="http://www.who.int/wer/2014/wer8921.pdf?ua=1">http://www.who.int/wer/2014/wer8921.pdf?ua=1</a> )

<b>2014_10</b>	<b>GVAP progress report</b>	For Decision	<p>SAGE will be expected to produce an independent annual report on progress with the Decade of Vaccines Global Vaccine Action Plan.</p> <p>Specially, SAGE will be asked to:</p> <ul style="list-style-type: none"> <li>• Review the DoV WG “Assessment report on DoV progress” based on the “GVAP Secretariat report 2014” and some Independent stakeholder submissions.</li> <li>• Make recommendations on any necessary changes to the formulation of the indicators, operational definitions and/or the processes for data collection.</li> <li>• Identify successes, challenges and areas where additional efforts or corrective actions by countries, regions, partners, donor agencies or other parties, are needed.</li> <li>• Provide recommendations and corrective actions for Members States, regions, partners, donor agencies “SAGE Assessment report on the Decade of Vaccines progress” which will be the basis of the “progress report” for the WHO Executive Board and World Health Assembly.</li> </ul>	Decade of Vaccines	<p>See GVAP ass. Report <a href="http://www.who.int/immunization/global_vaccine_action_plan/SAGE_DoV_GVAP_Assessment_report_2014_English.pdf?ua=1">http://www.who.int/immunization/global_vaccine_action_plan/SAGE_DoV_GVAP_Assessment_report_2014_English.pdf?ua=1</a></p>
<b>2014_10</b>	<b>Japanese Encephalitis vaccines</b>	For Decision	<p>Present SAGE with the report of the SAGE working group on Japanese encephalitis vaccines and request SAGE’s endorsement of the proposed recommendations. Discuss data gaps and research needs. Review the immunogenicity, effectiveness and safety profile of Japanese encephalitis vaccines and proposed schedules, including booster requirements and coadministration with other vaccines. SAGE recommendations on vaccine use will then be used to update the 2006 WHO position paper on the use of Japanese encephalitis vaccines.</p>	Vaccine specific	<p>February 2015 Japanese Encephalitis vaccine position paper <a href="http://apps.who.int/iris/bitstream/handle/10665/255353/WER9219.pdf?sequence=1">http://apps.who.int/iris/bitstream/handle/10665/255353/WER9219.pdf?sequence=1</a></p>

<b>2014_10</b>	<b>Meningococcal A conjugate vaccine impact and routine immunization schedule in infants and young children</b>	For Decision	<p>What are the preferred schedules for meningococcal A conjugate vaccine in infants and young children living in countries of the African meningitis belt to achieve sustainable disease control following the initial mass vaccination campaigns?</p> <p>This will lead to an update of the meningococcal position paper</p> <p>What are the gaps in policy-oriented information?</p>	Vaccine specific	February 2015 Meningococcal A conjugate vaccine position paper <a href="http://www.who.int/wer/2015/wer9008.pdf?ua=1">http://www.who.int/wer/2015/wer9008.pdf?ua=1</a>
<b>2014_10</b>	<b>Global polio eradication initiative</b>	For Decision	<p>For decision:</p> <ul style="list-style-type: none"> <li>· Type 2 risk mitigation strategy prior to OPV2 withdrawal</li> <li>· Type 2 risk assessment and response strategy after OPV2 withdrawal</li> <li>· Bio-containment strategy</li> <li>· mOPV2 stockpile policy</li> </ul> <p>For discussion:</p> <ul style="list-style-type: none"> <li>· Progress in eliminating wild and persistent cVDPV poliovirus</li> </ul>	Vaccine specific	SAGE endorsed the proposed risk-based approach for boosting immunity to type 2 poliovirus prior to OPV2 withdrawal, see SAGE Report <a href="http://www.who.int/wer/2014/wer8950.pdf?ua=1">http://www.who.int/wer/2014/wer8950.pdf?ua=1</a>
<b>2014_10</b>	<b>Hepatitis E vaccine</b>	For Decision	<p>Present SAGE with:</p> <ol style="list-style-type: none"> <li>1. a review of data regarding the global prevalence and burden of disease caused by hepatitis E</li> <li>2. a review of safety, efficacy, immunogenicity, cost effectiveness and programmatic issues related to the hepatitis E vaccine</li> <li>3. the hepatitis E vaccine pipeline SAGE will be expected to provide recommendations on the use of hepatitis E vaccine.</li> </ol>	Vaccine specific	May 2015 Hepatitis E vaccine position paper <a href="http://www.who.int/wer/2015/wer9018.pdf?ua=1">http://www.who.int/wer/2015/wer9018.pdf?ua=1</a>

<b>2014_10</b>	<b>Vaccine hesitancy</b>	For Decision	<p>SAGE will be presented with and asked to review and discuss the deliverables and conclusions of the Vaccine Hesitancy Working Group including:</p> <ul style="list-style-type: none"> <li>• The definition of hesitancy</li> <li>• The Matrix of determinants of hesitancy</li> <li>• The Results of the immunization managers' survey and a systematic review of the drivers of vaccine hesitancy and their impact</li> <li>• A systematic review of strategies of vaccine hesitancy</li> <li>• The proposed indicators and survey questions</li> <li>• The Landscape of organizations dealing with hesitancy</li> </ul> <p>SAGE will be expected to make a decision on the proposed recommendations on how deal with vaccine hesitancy.</p>	Programmatic challenge	<p>Comprehensive publication in Vaccine (special issue)</p> <p><a href="https://www.sciencedirect.com/journal/vaccine/vol/33/issue/34">https://www.sciencedirect.com/journal/vaccine/vol/33/issue/34</a></p>
<b>2015_04</b>	<b>Global polio eradication initiative</b>	For Decision	<p>For decision</p> <ul style="list-style-type: none"> <li>• Review/endorse the contingency plans if persistent cVDPV2 continue to circulate, • Review/endorse the proposed process for WHO to verify that essential poliovirus facilities certified by national authorities comply with GAP III</li> </ul> <p>For information</p> <ul style="list-style-type: none"> <li>• Review updated SIA calendar, • Review updates on preparation for OPV2 withdrawal (e.g. Implementation support for tOPV-bOPV switch in OPV2 withdrawal) and bOPV licensure</li> </ul>	Vaccine specific	<p>1.) SAGE endorsed the proposed cVDPV2 elimination strategies in Nigeria and Pakistan 2.) SAGE endorsed the proposed approach to verification of compliance of poliovirus containment in essential facilities. Under the WHO Global Action Plan (GAP III), facilities planning to handle or store type 2 poliovirus are requested to implement containment measures and appropriately manage associated biorisks. please see SAGE Report</p> <p><a href="http://www.who.int/wer/2015/wer9022.pdf?ua=1">http://www.who.int/wer/2015/wer9022.pdf?ua=1</a></p>

<b>2015_04</b>	<b>Reducing pain and distress at the time of vaccination</b>	For Decision	Recommendations on potential interventions to reduce pain and distress at the time of vaccination	Programmatic challenge	September 2015 Position papers on reducing pain at time of vaccination <a href="http://www.who.int/wer/2015/wer9039.pdf?ua=1">http://www.who.int/wer/2015/wer9039.pdf?ua=1</a>
<b>2015_04</b>	<b>Pertussis vaccination schedules</b>	For Decision	With primary focus on pertussis, review the evidence in support/against different schedules for DTP containing vaccines and the impact of different vaccination strategies. Update recommendations on the optimal schedules for DTP containing vaccines with a view to lead to the updating of the pertussis position paper.	Vaccine specific	August 2015 Pertussis vaccine position paper <a href="http://www.who.int/wer/2015/wer9035.pdf?ua=1">http://www.who.int/wer/2015/wer9035.pdf?ua=1</a>
<b>2015_10</b>	<b>Global Polio Eradication Initiative</b>	For Decision	For decision · Reaffirm the OPV2 withdrawal date of April 2016, after careful assessment of progress toward the following: · Elimination of all persistent cVDPV2, · Preparedness for OPV2 withdrawal, · Endorse the specific switch dates in April 2016 and the framework for monitoring tOPV withdrawal For information · To update SAGE on: · the current status of the polio eradication program, · the contingency planning for vaccine supply, · the status of polio legacy planning	Vaccine specific	SAGE reaffirmed that the withdrawal of OPV2 should proceed in April 2016. see SAGE Report Link: <a href="http://www.who.int/wer/2015/wer9050.pdf?ua=1">http://www.who.int/wer/2015/wer9050.pdf?ua=1</a>

<b>2015_10</b>	<b>Measles and rubella vaccines</b>	For Decision	<p>For discussion</p> <ul style="list-style-type: none"> <li>· To review the current status of global measles and rubella control and regional elimination</li> <li>· To review the plans for a Midterm Review of the Measles and Rubella Strategic plan</li> <li>· To review how existing data can be used to determine the target age range for M and MR SIAs</li> </ul> <p>For decision</p> <ul style="list-style-type: none"> <li>· Epidemiological settings in which a supplemental dose of MCV is recommended for infants aged &lt;9 months</li> <li>· Measles revaccination of HIV-infected children on antiretroviral therapy</li> </ul>	Vaccine specific	<p>Refined Policies on use MCV before 9 month of age and in HIV infected individuals, see SAGE Report Link:</p> <p><a href="http://www.who.int/wer/2015/wer9050.pdf?ua=1">http://www.who.int/wer/2015/wer9050.pdf?ua=1</a></p>
<b>2015_10</b>	<b>Malaria Vaccine Joint session of Malaria Policy Advisory Committee (MPAC)/SAGE</b>	For Decision	<p>Present SAGE and MPAC with the report of the Joint Technical Expert Group (JTEG) on the RTS,S malaria vaccine and request SAGE/MPAC's consideration of the proposed recommendations.</p> <p>SAGE/MPAC recommendations on vaccine use will then be used to write the first WHO position paper on the use of a malaria vaccine.</p>	Vaccine specific	<p>January 2016 Malaria vaccine position paper</p> <p><a href="http://apps.who.int/iris/bitstream/handle/10665/255353/WER9219.pdf?sequence=1">http://apps.who.int/iris/bitstream/handle/10665/255353/WER9219.pdf?sequence=1</a></p>

<b>2015_10</b>	<b>GVAP progress report</b>	For Decision	<p>SAGE will be expected to produce an independent annual report on progress with the Decade of Vaccines Global Vaccine Action Plan.</p> <p>Specially, SAGE will be asked to:</p> <ul style="list-style-type: none"> <li>· Review the DoV WG “Assessment report on DoV progress 2015” based on the “GVAP Secretariat report 2015” and some Independent stakeholder submissions.</li> <li>· Make recommendations on any necessary changes to the formulation of the indicators, operational definitions and/or the processes for data collection.</li> <li>· Identify successes, challenges and areas where additional efforts or corrective actions by countries, regions, partners, donor agencies or other parties, are needed.</li> <li>· Provide recommendations and corrective actions for Members States, regions, partners, donor agencies “SAGE Assessment report on the Decade of Vaccines progress” which will be the basis of the “progress report” for the WHO Executive Board and World Health Assembly.</li> </ul>	Decade of Vaccines	Assessment Report published; was sent to Governing bodies; Link: <a href="http://www.who.int/immunization/global_vaccine_action_plan/SAGE_GVAP_Assessment_Report_2015_EN.pdf?ua=1">http://www.who.int/immunization/global_vaccine_action_plan/SAGE_GVAP_Assessment_Report_2015_EN.pdf?ua=1</a>
<b>2016_04</b>	<b>Missed opportunities for vaccination</b>	For Decision	<p>SAGE will be:</p> <ul style="list-style-type: none"> <li>• Provided with an update on ongoing work to address missed opportunities for vaccination</li> <li>• Presented with the potential value and impact of the updated approach for assessing extent of, and implementing solutions to reduce missed opportunities for vaccination</li> <li>• Requested to endorse the updated approach for reducing missed opportunities</li> <li>• Asked to advise on the proposed framework for addressing missed opportunities and on the partner coordination mechanisms</li> </ul>	Programmatic challenge	WHO Strategy and various 2017 WHO documents on missed opportunities for vaccination <a href="http://www.who.int/immunization/programmes_systems/policies_strategies/MOV/en/">http://www.who.int/immunization/programmes_systems/policies_strategies/MOV/en/</a>

<b>2016_04</b>	<b>Dengue vaccine</b>	For Decision	Present SAGE with the report of the SAGE Working Group on Dengue Vaccines and Vaccination on the CYD dengue vaccine and request SAGE's consideration of the proposed recommendations. SAGE recommendations on vaccine use will then be used to write the first WHO position paper on the use of a dengue vaccine.	Vaccine specific	July 2016 Dengue vaccine position paper <a href="http://www.who.int/wer/2016/wer9130.pdf?ua=1">http://www.who.int/wer/2016/wer9130.pdf?ua=1</a>
<b>2016_10</b>	<b>Measles and rubella elimination</b>	For Decision	<p>FOR DISCUSSION</p> <ul style="list-style-type: none"> <li>• To review the current status of global measles and rubella control and regional elimination.</li> </ul> <p>FOR DECISION</p> <ul style="list-style-type: none"> <li>• SAGE is requested to review the Mid Term Review findings and recommendations and endorse the recommendations.</li> <li>• SAGE is requested to decide on whether or not to remove the introduction criteria for MCV2.</li> </ul>	Vaccine specific	Endorsment of mid term conclusions, request by SAGE for detailed guidance on country immunity gaps for tailored immunization strategies; Reinforcement of MCV2 strategy; see SAGE Report Link: <a href="http://apps.who.int/iris/bitstream/handle/10665/251810/WER9148.pdf;jsessionid=4A4DCF8267F77F0C59E7829BEB4A82D9?sequence=1">http://apps.who.int/iris/bitstream/handle/10665/251810/WER9148.pdf;jsessionid=4A4DCF8267F77F0C59E7829BEB4A82D9?sequence=1</a>

2016_10	<b>Maternal and neonatal tetanus elimination and overall tetanus prevention</b>	For Decision	Based on its working group input, SAGE will be expected to provide recommendations on: 1. resetting the agenda, with interim milestones, for achieving MNTE; 2. steps that could be taken to increase visibility and political advocacy of MNTE; 3. how to overcome known and anticipated bottlenecks to achieving MNTE, including recommendations on how achieving the above outcomes will require different approaches by setting or typology; 4. strategies for sustaining MNTE elimination in countries that have achieved MNTE with targeted immunization strategies, including recommendations on methods for documenting sustained elimination; 5. strategies to achieve broader tetanus prevention (i.e. including all age groups and both genders; 6. any necessary adjustments to the policy recommendations in the WHO tetanus position paper.	Vaccine specific	February 2017 Tetanus vaccine position paper <a href="http://apps.who.int/iris/bitstream/handle/10665/254582/WER9206.pdf?sequence=1">http://apps.who.int/iris/bitstream/handle/10665/254582/WER9206.pdf?sequence=1</a>
---------	---	--------------	--	------------------	---

2016_10	<b>GVAP progress report</b>	For Decision	<p>SAGE will be expected to produce an independent annual report on progress with the Decade of Vaccines Global Vaccine Action Plan.</p> <p>Specially, SAGE will be asked to:</p> <ul style="list-style-type: none"> <li>• Review the DoV WG “Assessment report on DoV progress 2016” based on the “GVAP Secretariat report 2016”, regional reports on the implementation of regional vaccine action plans, priority country reports and some Independent stakeholder submissions.</li> <li>• Make recommendations on any necessary changes to the formulation of the indicators, operational definitions and/or the processes for data collection.</li> <li>• Identify successes, challenges and areas where additional efforts or corrective actions by countries, regions, partners, donor agencies or other parties, are needed. Provide recommendations and corrective actions for Members States, regions, partners, donor agencies</li> </ul> <p>“SAGE Assessment report on the Decade of Vaccines progress” which will be the basis of the “progress report” for the WHO Executive Board and World Health Assembly.</p>	Decade of Vaccines	<p>Assessment Report published; was sent to Governing bodies; Link: <a href="http://www.who.int/immunization/global_vaccine_action_plan/SAGE_GVAP_Assessment_Report_2016_EN.pdf?ua=1">http://www.who.int/immunization/global_vaccine_action_plan/SAGE_GVAP_Assessment_Report_2016_EN.pdf?ua=1</a></p>
---------	-------------------------------------	-----------------	---	--------------------------	---

2016_10	<b>Hepatitis B vaccination</b>	For Decision	<p>Present SAGE with updated evidence on hepatitis B infection-related burden, immunogenicity and safety of hepatitis B containing vaccines, the impact of hepatitis B containing vaccines immunization programmes and the thermostability of the monovalent formulation. Focus is on evidence relevant to low- and middle-income countries.</p> <p>Request SAGE's consideration of the following questions:</p> <ul style="list-style-type: none"> <li>• Do the current schedule recommendations require any modifications?</li> <li>• What is the impact of the vaccination programme on the epidemiology of hepatitis B when providing a timely vaccine birth dose?</li> <li>• Does the available evidence support flexibility in the requirement for cold chain storage of hepatitis B vaccines in order to expand the delivery of the birth dose?</li> </ul> <p>SAGE recommendations may be used to update the 2009 WHO position paper on the use of hepatitis B vaccines.</p>	Vaccine specific	<p>July 2017 Hepatitis B vaccine position paper  <a href="http://apps.who.int/iris/bitstream/handle/10665/255841/WER9227.pdf?sequence=1">http://apps.who.int/iris/bitstream/handle/10665/255841/WER9227.pdf?sequence=1</a></p>
---------	--------------------------------	--------------	---	------------------	--

<b>2016_10</b>	<b>HPV vaccines</b>	For Decision	<p>Present SAGE with updated evidence on HPV-related burden, HPV vaccines, impact of HPV immunization programmes, and modelling of impact of HPV immunization schedules and strategies. Focus is on evidence relevant to low- and middle-income countries. Request SAGE's consideration of the following questions: What is the incremental effectiveness and cost-effectiveness for cervical cancer prevention of different HPV vaccines based on girls-only immunization?</p> <ul style="list-style-type: none"> <li>• What is the incremental effectiveness and cost-effectiveness for prevention of HPV-related diseases of adolescent gender-neutral HPV immunization compared to girls-only HPV immunization?</li> <li>• What is the incremental effectiveness and cost effectiveness for cervical cancer prevention of multiple age cohort HPV immunization of females (within a defined age range) compared to single age cohort immunization of girls-only or of both girls and boys aged 9–13 years? SAGE recommendations may be used to update WHO position paper on HPV vaccines, which was published in October 2014.</li> </ul>	Vaccine specific	<p>May 2017 HPV vaccine position paper  <a href="http://apps.who.int/iris/bitstream/handle/10665/255353/WER9219.pdf?sequence=1">http://apps.who.int/iris/bitstream/handle/10665/255353/WER9219.pdf?sequence=1</a></p>
<b>2016_10</b>	<b>Yellow Fever</b>	For Decision	<p>SAGE is asked to provide feedback on the general approach of the "Global Strategy for Eliminating Yellow fever Epidemics (EYE)".</p> <p>SAGE is asked to provide recommendations and research priorities for fractional dose use of Yellow fever vaccine as a response to major outbreaks.</p>	Vaccine specific	<p>1.) EYE Strategy endorsed, 2) YF Fractional Dose PP:  <a href="http://www.who.int/immunization/policy/position_papers/yellow-fever/en/">http://www.who.int/immunization/policy/position_papers/yellow-fever/en/</a></p>

<b>2017_04</b>	<b>Use of oral cholera vaccines</b>	For Decision	SAGE will be presented with a report of the SAGE working group on oral cholera vaccines and expected to provide recommendations on the use of oral cholera vaccines with particular focus on cholera endemic settings, humanitarian crisis and on the control of cholera outbreaks. The SAGE recommendations will then be reflected in an updated WHO vaccine position paper on the use of cholera vaccines with a target publication date of Q3 2017.	Vaccine specific	August 2017 Cholera vaccine position paper <a href="http://apps.who.int/iris/bitstream/handle/10665/258763/WER9234.pdf?sequence=1">http://apps.who.int/iris/bitstream/handle/10665/258763/WER9234.pdf?sequence=1</a>
<b>2017_04</b>	<b>Ebola vaccines Update with the development of Ebola vaccines and implications to inform future policy recommendations</b>	For Decision	<p>For information</p> <p>Present SAGE with data on immunogenicity, efficacy, effectiveness and safety of candidate Ebola vaccines and, on the observed and projected impact of different vaccination strategies using compassionate use data and from mathematical models.</p> <p>For decision</p> <p>Request SAGE's recommendations on the following: · Are there remaining challenges that may prevent access to Ebola vaccines in future outbreaks, and if yes can SAGE make recommendations on how these might be addressed. · Is the current evidence sufficient for SAGE to make recommendations regarding the use of Ebola vaccines (e.g. rVSV and the Russian vaccine) in case of another Ebola outbreak (prelicensure and/or post licensure)? -If yes, which recommendations can be proposed? -If not, what key data are missing?</p>	Vaccine specific	Ebola Policy published in meeting report; Link: <a href="http://apps.who.int/iris/bitstream/10665/255611/1/WER9222.pdf?ua=1">http://apps.who.int/iris/bitstream/10665/255611/1/WER9222.pdf?ua=1</a>

<b>2017_04</b>	<b>Diphtheria</b>	For Decision	SAGE will be presented with an analysis of recent diphtheria outbreaks as well as with a systematic review on the duration of protection of diphtheria vaccination. SAGE will be asked to decide whether there is sufficient evidence to revisit the recommendation on the administration of decennial diphtheria booster doses to adults and synchronization of schedules in light of the recently revised position papers on pertussis and tetanus vaccines. The aim will be to lead to an updating of the 2006 diphtheria vaccine WHO position paper. SAGE will further be informed of the current status of diphtheria antitoxin supply and plans to ensure availability.	Vaccine specific	August 2017 Diphtheria vaccine position paper <a href="http://apps.who.int/iris/bitstream/handle/10665/258681/WER9231.pdf?sequence=1">http://apps.who.int/iris/bitstream/handle/10665/258681/WER9231.pdf?sequence=1</a>
<b>2017_10</b>	<b>Typhoid vaccines</b>	For Decision	Present SAGE with the report of the SAGE Working Group on Typhoid Vaccines, including: • The evidence review on disease and economic burden, increasing threat of antimicrobial resistance (AMR) and effectiveness and safety of typhoid vaccines. • Draft recommendations on vaccine use for typhoid control (in context of other interventions), with a focus on newly licensed typhoid conjugate vaccines, as well as an update on the currently recommended Vi polysaccharide (ViPS) and Ty21a vaccines. Updated SAGE recommendations on typhoid vaccine use will be used to update the 2008 WHO position paper on typhoid vaccines.	Vaccine specific	March 2018 Typhoid vaccine position paper <a href="http://apps.who.int/iris/bitstream/handle/10665/272272/WER9313.pdf?ua=1">http://apps.who.int/iris/bitstream/handle/10665/272272/WER9313.pdf?ua=1</a>

<b>2017_10</b>	<b>Polio eradication initiative</b>	For Decision	<p>For information</p> <p>To update SAGE on:</p> <ul style="list-style-type: none"> <li>• The current status of the polio eradication program, including the IPV supply situation, risk assessment of types 1 and 3 before bivalent oral polio vaccine (bOPV) withdrawal and the post certification strategy.</li> <li>• The status of implementation of fractional IPV in the routine immunization.</li> <li>• The preliminary discussions on assessment criteria for OPV withdrawal. For decision</li> </ul> <p>To seek SAGE's recommendations on: Proposed approach to prioritize IPV allocation in tier 3 and 4 countries, based on the risk ranking.</p> <ul style="list-style-type: none"> <li>• IPV catch-up for children in countries which delayed the introduction of IPV or had stock out due to supply shortage.</li> </ul>	Vaccine specific	Specific recommendation in SAGE meeting report; Link: <a href="http://apps.who.int/iris/bitstream/10665/259533/1/WER9248.pdf?ua=1">http://apps.who.int/iris/bitstream/10665/259533/1/WER9248.pdf?ua=1</a>
<b>2017_10</b>	<b>GVAP progress report</b>	For Decision	<p>SAGE will be expected to produce an independent annual report on progress with the Decade of Vaccines Global Vaccine Action Plan.</p> <p>Specially, SAGE will be asked to:</p> <ul style="list-style-type: none"> <li>• Review the DoV WG "Assessment report on DoV progress 2017" based on the "GVAP Secretariat report 2017", regional reports on the implementation of regional vaccine action plans, priority country reports and some independent stakeholder submissions.</li> <li>• Make recommendations on any necessary changes to the formulation of the indicators, operational definitions and/or the processes for data collection.</li> <li>• Identify successes, challenges and areas where additional efforts or corrective actions by countries, regions, partners, donor agencies or other parties, are needed.</li> </ul> <p>Provide recommendations and corrective actions for Member States, regions, partners, donor agencies "SAGE</p>	Decade of Vaccines	Assessment Report published; was sent to Governing bodies; Link: <a href="http://www.who.int/immunization/web_2017_sage_gvap_assessment_report_en.pdf?ua=1">http://www.who.int/immunization/web_2017_sage_gvap_assessment_report_en.pdf?ua=1</a>

---

Assessment report on the Decade of Vaccines progress”  
which will be the basis of the “progress report” for the  
2018 WHO Executive Board and World Health Assembly.  
Review the immunization related indicators proposed as  
part of the Sustainable Development Goals indicator and  
make a final decision on these indicators.  
SAGE will further be presented with the preliminary plans  
for Global Immunization Strategy 2021-30.

---

2017_10	<b>Rabies vaccines</b>	For Decision	<p>Based on the evidence presented, SAGE is expected to review and endorse draft recommendations related to the following questions:</p> <p>Question 1: Does novel evidence support the use of PREP in particular sub-populations, apart from persons bearing an occupational rabies exposure risk?</p> <p>Question 2: Does novel evidence support the need for rabies booster doses in persons at continual or frequent risk of occupational rabies exposure?</p> <p>Question 3: Can the duration of the entire course of current PREP regimens be reduced while maintaining immunogenicity and clinical protection?</p> <p>Question 4: Can the number of doses administered in current PREP regimens be reduced while maintaining immunogenicity and clinical protection?</p> <p>Question 5: Which (operational) parameters affect cost-effectiveness of intradermal (ID) compared to intramuscular (IM) administration route of PEP? a. in urban settings; b. in rural settings.</p> <p>Question 6: Can the duration of the entire course of current PEP regimens be reduced while maintaining immunogenicity and clinical protection?</p> <p>Question 7: Can the number of doses administered in current PEP regimens be reduced while maintaining immunogenicity and clinical protection?</p> <p>Question 8: Does novel evidence support recommendations on modified PEP protocols vs current PEP protocols for specific risk groups of rabies exposed patients, such as: Immuno-compromised patients (e.g. HIV-infected); patients concurrently using antimalarial drugs; pregnant women; bat exposures (i.e. for bat lyssavirus)?</p> <p>Question 9: Does a change in route of administration (IM or ID) during a single course of a PEP regimen affect</p>	Vaccine specific	<p>April 2018 Rabies vaccine position paper  <a href="http://www.who.int/wer/2016/wer9112.pdf?ua=1">http://www.who.int/wer/2016/wer9112.pdf?ua=1</a></p>
---------	------------------------	--------------	--	------------------	--

immunogenicity of PEP?

Question 10: Are there novel approaches to RIG (-sparing) injection vs current practice as part of PEP for category III exposed patients?

Question 11: Is there clinical equivalence in the safe use of eRIG compared to hRIG in category III exposed patients?

Question 12: Is there clinical equivalence in the efficacious use of eRIG compared to hRIG in category III exposed patients?

Question 13: Can monoclonal antibodies be safely and efficaciously administered in category III exposed patients compared to standard RIG?

Question 14: In cases of RIG shortage and constraints, can subcategories of patients be identified who should be given highest priority for RIG administration?

<b>2017_10</b>	<b>Pneumococcal conjugate vaccines (PCV)</b>	For Decision	<p>SAGE will be expected to review evidence related to the following questions and update recommendations on the use of Pneumococcal conjugate vaccines accordingly:</p> <p>1) In the general population, what overall effectiveness and impact does a 2p+1 PCV dosing schedule elicit as compared to a 3p+0 PCV dosing schedule?</p> <p>2) In the general population, what overall effectiveness and impact does PCV10 elicit as compared to PCV13?</p> <p>3) In the general population, what additional value does catch-up vaccination with 1 or 2 doses of PCV in vaccine naïve children above the birth cohort have as compared with vaccination of only the birth cohort at the time of introduction (or PCV product switch)?</p>	Vaccine specific	Vaccine Position Paper in Preparation (Q1 2019)
<b>2017_10</b>	<b>Measles and rubella elimination</b>	For Decision	<p>For information:</p> <ul style="list-style-type: none"> <li>• Global update on measles and rubella</li> <li>• Progress on the implementation of recommendations from the midterm review.</li> </ul> <p>For recommendations on:</p> <ul style="list-style-type: none"> <li>• Global criteria for country categorization.</li> <li>• What level of population immunity is needed to achieve herd immunity (age-specific immunity thresholds).</li> <li>• The possibility and eventual need to vaccinate infants less than 6 months of age.</li> <li>• Review evidence and provide policy guidance related to revaccination of HIV infected adults.</li> </ul>	Vaccine specific	Specific recommendation in SAGE meeting report; Link: <a href="http://apps.who.int/iris/bitstream/10665/259533/1/WER9248.pdf?ua=1">http://apps.who.int/iris/bitstream/10665/259533/1/WER9248.pdf?ua=1</a>

<b>2017_10</b>	<b>Bacille Calmette-Guerin (BCG) vaccines</b>	For Decision	<p>Present SAGE with the report of the SAGE BCG Working Group and request SAGE's consideration of the proposed recommendations.</p> <p>SAGE will particularly be asked to consider the optimal timing of vaccination, the vaccination of HIV exposed and HIV infected children, the duration of protection and need for revaccination, the effect of BCG co-administration with other vaccines, and the potential role of BCG in the control of leprosy.</p> <p>SAGE recommendations on vaccine use will then be used to update the WHO Position Paper on BCG.</p>	Vaccine specific	<p>February 2018 BCG vaccine position paper</p> <p><a href="http://apps.who.int/iris/bitstream/handle/10665/260306/WER9308.pdf;jsessionid=0D838549FC7E3659908790F17CCA1E9A?sequence=1">http://apps.who.int/iris/bitstream/handle/10665/260306/WER9308.pdf;jsessionid=0D838549FC7E3659908790F17CCA1E9A?sequence=1</a></p>
----------------	---	--------------	--	------------------	--